Exelixis Business Operations Contracts & Agreements

63 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Fifth Amendment dated August 24, 2023, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Collaboration Agreements
Exelixis
Biotechnology
2023
Fourth Amendment dated October 11, 2022, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Collaboration Agreements
Exelixis
Biotechnology
2023
Second Amendment dated May 7, 2019, to Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited
Collaboration Agreements
Exelixis
Biotechnology
2022
Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited
Collaboration Agreements
Exelixis
Biotechnology
DE
2022
Third Amendment dated December 10, 2021, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Supply Agreements
Exelixis
Biotechnology
2022
First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Supply Agreements
Exelixis
Biotechnology
2021
Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Supply Agreements
Exelixis
Biotechnology
NY
2021
Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Collaboration Agreements
Exelixis
Biotechnology
2021
Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Collaboration Agreements
Exelixis
Biotechnology
2021
First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Collaboration Agreements
Exelixis
Biotechnology
2021
Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Collaboration Agreements
Exelixis
Biotechnology
NY
2021
Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited
Collaboration Agreements
Exelixis
Biotechnology
2020
Second Amendment dated May 7, 2020, to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Myers Squibb...
Collaboration Agreements
Exelixis
Biotechnology
2020
Amendment No. 3 dated November 22, 2019, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company
Collaboration Agreements
Exelixis
Biotechnology
2020
Amendment No. 2 dated August 15, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Myers Squibb Company
Collaboration Agreements
Exelixis
Biotechnology
2019
Second Amendment dated May 17, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited
Collaboration Agreements
Exelixis
Biotechnology
2019
Second Amendment dated May 17, 2019, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Supply Agreements
Exelixis
Biotechnology
2019
Amendment No. 1 dated March 8, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company
Collaboration Agreements
Exelixis
Biotechnology
2019
Amendment #3 dated May 29, 2018, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human...
Development Agreements
Exelixis
Biotechnology
2019
Ono Territorial Supplemental Agreement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Ono Pharmaceutical Co., Ltd. and...
Collaboration Agreements
Exelixis
Biotechnology
NY
2018
Supplement dated July 6, 2018 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Takeda...
Collaboration Agreements
Exelixis
Biotechnology
NY
2018
First Amendment dated July 6, 2018 to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb...
Collaboration Agreements
Exelixis
Biotechnology
2018
First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited
Collaboration Agreements
Exelixis
Biotechnology
2018
First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Supply Agreements
Exelixis
Biotechnology
2018
Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS
Collaboration Agreements
Exelixis
Biotechnology
2018
Second Amendment dated September 14, 2017, to Collaboration and License Agreement by and between Exelixis, Inc. and Ipsen Pharma SAS
Collaboration Agreements
Exelixis
Biotechnology
2017
Third Amendment to the Collaboration Agreement
Collaboration Agreements
Exelixis
Biotechnology
2017
SUPPLEMENT TO THE CLINICAL TRIAL COLLABORATION AGREEMENT
Collaboration Agreements
Exelixis
Biotechnology
NY
2017
CLINICAL TRIAL COLLABORATION AGREEMENT
Collaboration Agreements
Exelixis
Biotechnology
NY
2017
COLLABORATION AND LICENSE AGREEMENT
Collaboration Agreements
Exelixis
Biotechnology
DE
2017
First Amendment to the Collaboration Agreement
Collaboration Agreements
Exelixis
Biotechnology
2017
COLLABORATION AGREEMENT
Collaboration Agreements
Exelixis
Biotechnology
CA
2017
FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT
Collaboration Agreements
Exelixis
Biotechnology
2017
Amendment #2 Cooperative Research and Development Agreement #11-1-00006 Clinical Development of Exelixis Inc.s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial...
Development Agreements
Exelixis
Biotechnology
2017
Amendment #1 Cooperative Research and Development Agreement #11-1-00006 Clinical Development of Exelixis Inc.s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial...
Development Agreements
Exelixis
Biotechnology
2017
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH
Development Agreements
Exelixis
Biotechnology
DC
2017
COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS 2017 Cash Compensation for Non-Employee Directors Board of DirectorsRetainer Fee $25,000 Additional Chair Retainer Fee $30,000...
Development Agreements
Exelixis
Biotechnology
2017
AMENDED AND RESTATED COLLABORATION AGREEMENT
Collaboration Agreements
Exelixis
Biotechnology
DE
2016
SUPPLY AGREEMENT
Supply Agreements
Exelixis
Biotechnology
NY
2016
COLLABORATION AND LICENSE AGREEMENT
Collaboration Agreements
Exelixis
Biotechnology
NY
2016